Document is current
Any future updates will be listed below
-
Authors
Shi, Yun-feng
Ju, Lin-hang
Wang, Kang-ning
Pan, Yu
Zou, Yu-ying
Lu, Xi
Tuo, Ling
Zou, Wen-tao
Wei, Ming-wei
Zhao, Yan-wei
Pan, Hong-xing
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct07071701 at ClinicalTrials.govDocuments that mention this clinical trial
Post-marketing Safety Surveillance of 23-Valent Pneumococcal Polysaccharide Vaccine Administered Alone and Concomitantly with Influenza Vaccine in Individuals Aged 2 Years and Older in China
https://doi.org/10.1007/s40121-026-01309-4
- License Information
-
More Information
Article History
Received: 24 November 2025
Accepted: 22 January 2026
First Online: 23 February 2026
Declarations
:
: All authors declare that they have no conflicts of interest. Ming-wei Wei, Hong-xing Pan, Yun-feng Shi, Lin-hang Ju, Yu Pan, and Kang-ning Wang have nothing to disclose. Yu-ying Zou, Xi Lu, Ling Tuo, Wen-tao Zou and Yan-wei Zhao are employees of Sinovac Biotech Co., Ltd.
: The study was carried out from May 25, 2022 to March 31, 2024, and the study was conducted in accordance with the principles of the Helsinki Declaration of 1964 and its later amendments and was approved by the Ethics Committee of Jiangsu Provincial Center for Disease Control and Prevention (reference no. JSJK2022-A025-01). All participants in the active surveillance group signed informed consent before enrollment. Informed consent of passive surveillance was waived as a result of the study using de-identified data. The trial was retrospectively registered because the study was initiated as a post-marketing safety surveillance program, and trial registration was completed after study initiation.
